(Q36653663)

15 August 2017

1 reference

title

A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis (English)

1 reference

15 August 2017

Sofia Baka

1

1 reference

15 August 2017

Andrew R Clamp

series ordinal

2

1 reference

15 August 2017

Gordon C Jayson

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Therapeutic Targets

15 August 2017

published in

1 reference

15 August 2017

volume

10

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

867-876

1 reference

VEGF and the quest for tumour angiogenesis factors

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Recent developments in the cell biology of basic fibroblast growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

VEGF: an update on biological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Endothelial receptor tyrosine kinases involved in angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Angiogenesis as a target for tumor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

VEGF inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Monoclonal antibody strategies to block angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Angiogenesis inhibitors in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Therapeutic potential of inhibitory VEGF splice variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Surrogate markers in antiangiogenesis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Predicting benefit from anti-angiogenic agents in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Angiogenic growth factors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis AttenuatesIn vivoTumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

A cancer therapy resistant to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.867

10.1517/14728222.10.6.867

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference